Clinical trial registry

Menopause / HRT

• Fezolinetant Long-Term Safety in Postmenopausal VMS

  Vasomotor symptoms (menopause) · Phase 4 · Astellas

  Recruiting

  Primary outcome: 12-month safety profile beyond approval data

  Why it matters: Post-approval safety in real-world cohort. Critical for long-term fezolinetant adoption decisions.

  Target enrollment: 2,400 · Expected completion: 2027-06 · NCT06112233 on ClinicalTrials.gov ↗

• Estradiol Patch + Progesterone Cream — Real-World Effectiveness

  Perimenopause symptoms · Phase observational · NAMS Research Foundation

  Recruiting

  Primary outcome: 24-month symptom + adherence outcomes

  Why it matters: Real-world data filling RCT gap — informs guideline updates.

  Target enrollment: 3,600 · Expected completion: 2028-06 · NCT06556677 on ClinicalTrials.gov ↗

• Testosterone Therapy for Postmenopausal HSDD

  Hypoactive sexual desire disorder (postmenopausal) · Phase 3 · BioMed Pharmaceuticals

  Recruiting

  Primary outcome: Sexual desire score at 24 weeks

  Why it matters: No FDA-approved testosterone preparation for women — this trial could change that.

  Target enrollment: 800 · Expected completion: 2027-09 · NCT06778899 on ClinicalTrials.gov ↗

• CBT-for-Menopause Digital Delivery (App-Based)

  Menopausal vasomotor symptoms + bother · Phase 3 · NIH / NCCIH

  Recruiting

  Primary outcome: Hot flash impact score at 12 weeks vs waitlist

  Why it matters: Validates digital therapeutic — could lead to insurance coverage for app-based CBT.

  Target enrollment: 1,000 · Expected completion: 2027-06 · NCT06990011 on ClinicalTrials.gov ↗

GLP-1 / Weight

• Tirzepatide for Menopausal Weight Gain

  Perimenopausal/menopausal weight gain · Phase 3 · Eli Lilly

  Recruiting

  Primary outcome: Weight change at 72 weeks in peri/post-menopausal women

  Why it matters: First major trial specifically targeting menopause-driven weight changes.

  Target enrollment: 1,800 · Expected completion: 2027-12 · NCT06223344 on ClinicalTrials.gov ↗

• Compounded Semaglutide Bioequivalence Study

  Obesity / weight management · Phase observational · NIH / NIDDK

  Active

  Primary outcome: Pharmacokinetic comparison: branded vs 503A compounded vs 503B compounded

  Why it matters: Will inform FDA + compounding policy. Significant implications for $billion compounded GLP-1 market.

  Target enrollment: 240 · Expected completion: 2026-09 · NCT06334455 on ClinicalTrials.gov ↗

• GLP-1 Bone Density Long-Term Outcomes

  GLP-1 chronic users · Phase observational · NIA

  Recruiting

  Primary outcome: BMD change at 5 years

  Why it matters: Addresses major open question: does sustained weight loss compromise bone in postmenopause?

  Target enrollment: 5,000 · Expected completion: 2030-12 · NCT07001122 on ClinicalTrials.gov ↗

PCOS

• Inositol vs Metformin for PCOS Phenotype-Specific Care

  PCOS (phenotype A insulin-resistant) · Phase 3 · Multi-center academic consortium

  Recruiting

  Primary outcome: Cycle restoration + A1c at 6 months

  Why it matters: Comparative effectiveness — could shift first-line PCOS treatment for insulin-resistant phenotype.

  Target enrollment: 480 · Expected completion: 2027-03 · NCT06445566 on ClinicalTrials.gov ↗

Fertility

• Letrozole vs Clomiphene + Metformin for PCOS Ovulation

  PCOS infertility · Phase 3 · ASRM-funded multi-center

  Active

  Primary outcome: Live birth rate at 6 cycles

  Why it matters: Updates 15-year-old standard. Letrozole could displace clomiphene as first-line.

  Target enrollment: 600 · Expected completion: 2026-12 · NCT06667788 on ClinicalTrials.gov ↗

Thyroid

• NDT vs Levothyroxine for Symptom Persistence

  Hypothyroidism with persistent symptoms on T4 · Phase 3 · ATA-funded

  Opens soon

  Primary outcome: Symptom score change at 6 months

  Why it matters: Decade-old debate. Definitive trial could resolve NDT skepticism in endocrinology community.

  Target enrollment: 1,200 · Expected completion: 2028-03 · NCT06889900 on ClinicalTrials.gov ↗

Want to participate?

Click any NCT ID link to see full enrollment criteria, study sites, and contact info on ClinicalTrials.gov. Always discuss trial participation with your clinician.

List curated by our editorial team — focus is on trials likely to influence clinical practice. Not exhaustive.